Correlation of serum parameters with disease severity, exacerbations and hospitalizations in patients with Non-cystic fibrosis bronchiectasis

Authors

  • John Sonia Kallarakal Department of Pulmonary Medicine, Government Medical College, Ernakulam, Kerala, India
  • Fathahudeen A. Department of Pulmonary Medicine, Government Medical College, Ernakulam, Kerala, India
  • K. G. R. Mallan Department of Pulmonary Medicine, Government Medical College, Ernakulam, Kerala, India
  • Manjula V. D. Department of Community Medicine, Government Medical College, Ernakulam, Kerala, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20192490

Keywords:

Albumin, ANC, BSI, CRP, FACED, Hb, NCFB

Abstract

Background: The factors essential to define the severity and the prognosis of subjects with NCFB have not been sufficiently assessed. A prospective observational study was conducted to assess the serum parameters, their correlation with BSI (bronchiectasis severity index) and FACED (FEV1% predicted, age, chronic colonization by pseudomonas aeruginosa, extension by radiological assessment and dyspnoea) score in assessing disease severity and respiratory hospitalizations in patients with NCFB.

Methods: About 76 clinically stable patients diagnosed as NCFB were included. Data extraction was done using structured proforma. The BSI and FACED scores were calculated. The serum parameters albumin, CRP (C-reactive protein), ANC (Absolute neutrophil count) and Hb (hemoglobin) levels were estimated. The number of exacerbations and hospitalizations during the 6 months follow up period were recorded.

Results: The mean value of the serum parameters albumin, CRP, absolute neutrophil count (ANC) and Hb were 3.86 (95% CI 3.77- 3.95), 19.61 (95% CI 15.53 -23.68), 8632.95 (95% CI 7258.5-10068) and 12.3 (95% CI 11.84- 12.74) respectively. There was strong negative correlation between serum albumin and the BSI and FACED score. The mean exacerbations and hospitalizations during the 6 months follow up period were 3.3 (95% CI 2.93-3.65) and 1.14 (95% CI 0.85-1.44) respectively.

Conclusions: The serum albumin level exhibited strong correlation and was identified as a variable associated with the BSI and FACED scores. Further studies in this direction are needed for use of serum parameters in severity assessment.

References

Pasteur MC, Bilton D, Hill AT. British thoracic society guideline for non-CF bronchiectasis. Thorax. 2010;65(1):1-58.

Ringshausen FC, de Roux A, Pletz MW. Bronchiectasis-associated hospitalizations in Germany, 2005-2011: a population-based study of disease burden and trends. PLoS One. 2013;8:e71109.

Quint JK, Millett ER, Joshi M. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J. 2016;47:186-93.

Weycker D, Edelsberg JE, Oster G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med. 2005;12:205-9.

Seitz AE, Olivier KN, Adjemian J. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000-2007. Chest. 2012;142:4329.

Wong C, Jayaram L, Karalus N. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380:660-7.

Roberts ME, Lowndes L, Milne DG, Wong CA. Socioeconomic deprivation, readmissions, mortality and acute exacerbations of bronchiectasis. Intern Med J. 2012;42:e129-e36.

Aliberti S, Lonni S, Dore S, McDonnell MJ, Goeminne PC, Dimakou K, et al. Clinical phenotypes in adult patients with bronchiectasis. Eur Respir J. 2016; 47:1113-22.

Martinez-Garcia MA, Vendrell M, Giron R, Maiz-Carro L, de la Rosa Carrillo D, de Gracia J, et al. The multiple faces of non-cystic fibrosis bronchiectasis: A cluster analysis approach. Ann. Am. Thorac Soc. 2016;13:1468-75.

Saleh AD, Hurst Jr. How to assess the severity of bronchiectasis. Eur Respir J. 2014;43:1217-9.

Lim HY, Abisheganaden JA, Lim AYH. Serum predictors for outcome of hospitalization during exacerbation of bronchiectasis in adults. Am J Resp Critic Care Med. 2015;191:A2446.

Martinez-Garcia MA, de Gracia J, Relat MV. Multidimensional approach to non-cystic fibrosis bronchiectasis the FACED score. Eur Respir J. 2014;43:1357-67.

Chalmers JD, Goeminne P, Aliberti S. The bronchiectasis severity indexes an international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576-85.

McDonnell MJ, Aliberti S, Goeminne PC, Dimakou K, Zucchetti SC, Davidson J, et al. Multidimensional severity assessment in bronchiectasis: An analysis of seven European cohorts. Thorax. 2016;71(12):1110-8.

Saxer S, Gompelmann D, Eberhardt R, Fortin M, Kemp SV, Shah PL, et al. Joint chest-SGP congress 2017. Basel, Switzerland, 7-9 June 2017: Abstracts. Respirat. 2017;94(1):76-156.

Ip M, Lam WK, Chan JC, Liong E. Systemic effects of inflammation in bronchiectasis. Respirat Med. 1991;85(6):521.

Boussoffara L, Boudawara N, Touil I, Khelifa MB, Sakka M, Knani J. Nutritional status in patients with bronchiectasis. European Respirat J. 2012;40:P599.

Downloads

Published

2019-05-29

How to Cite

Kallarakal, J. S., A., F., Mallan, K. G. R., & D., M. V. (2019). Correlation of serum parameters with disease severity, exacerbations and hospitalizations in patients with Non-cystic fibrosis bronchiectasis. International Journal of Research in Medical Sciences, 7(6), 2151–2156. https://doi.org/10.18203/2320-6012.ijrms20192490

Issue

Section

Original Research Articles